Email updates

Keep up to date with the latest news and content from BMC Genomics and BioMed Central.

Open Access Research article

Treatment-independent miRNA signature in blood of wilms tumor patients

Jana Schmitt1*, Christina Backes1, Nasenien Nourkami-Tutdibi2, Petra Leidinger1, Stephanie Deutscher1, Markus Beier3, Manfred Gessler4, Norbert Graf2, Hans-Peter Lenhof5, Andreas Keller1 and Eckart Meese1

Author Affiliations

1 Department of Human Genetics, Saarland University, 66421 Homburg/Saar, Germany

2 Department of Pediatric Oncology and Hematology, Medical School, Saarland University, 66421 Homburg, Germany

3 febit group, 69120 Heidelberg, Germany

4 Developmental Biochemistry, Biocenter, University of Würzburg, 97074 Würzburg, Germany

5 Center for Bioinformatics, Saarland University, 66041 Saarbrücken, Germany

For all author emails, please log on.

BMC Genomics 2012, 13:379  doi:10.1186/1471-2164-13-379

Published: 7 August 2012

Abstract

Background

Blood-born miRNA signatures have recently been reported for various tumor diseases. Here, we compared the miRNA signature in Wilms tumor patients prior and after preoperative chemotherapy according to SIOP protocol 2001.

Results

We did not find a significant difference between miRNA signature of both groups. However both, Wilms tumor patients prior and after chemotherapy showed a miRNA signature different from healthy controls. The signature of Wilms tumor patients prior to chemotherapy showed an accuracy of 97.5% and of patients after chemotherapy an accuracy of 97.0%, each as compared to healthy controls.

Conclusion

Our results provide evidence for a blood-born Wilms tumor miRNA signature largely independent of four weeks preoperative chemotherapy treatment.